Our result revealed that higher levels of CRP are associated with shorter OS, with an HR of 1.87 (95% CI: 1.28–2.75; P = 0.001), indicating that high serum levels of CRP before treatment may be a negative prognostic factor for patients with bone cancers. This evidence concerns the gene CRP and bone cancer.